Treatment of non-alcoholic fatty liver disease

L A Adams, P Angulo

Non-alcoholic fatty liver disease (NAFLD) is common and may progress to cirrhosis and its complications. The pathogenesis of steatosis and cellular injury is thought to be related mostly to insulin resistance and oxidative stress. Therefore, management entails identification and treatment of metabolic risk factors, improving insulin sensitivity, and increasing antioxidant defences in the liver. Weight loss and exercise improve insulin sensitivity. Bariatric surgery may improve liver histology in patients with morbid obesity. Insulin sensitising drugs showed promise in pilot trials as have a number of hepatoprotective agents. Further randomised, well controlled trials are required to determine the efficacy of these drugs.

PATHOGENESIS

The pathogenesis of NAFLD is not fully understood, however the finding that not all patients with steatosis develop hepatic inflammation and hepatocellular damage has led to the hypothesis that different pathogenic factors lead firstly to hepatic steatosis and secondly to hepatic damage (“the second hit”). Accumulation of hepatic fat is closely linked to insulin resistance, which increases lipolysis of peripheral adipose tissue with resultant increased fat influx into the liver in the form of free fatty acids. Furthermore, insulin resistance promotes de novo triglyceride synthesis within the liver and inhibits fatty acid oxidation thereby promoting triglyceride accumulation. Therefore, improving insulin sensitivity has been a key strategy in the treatment of NAFLD.

It is unknown what “second hit” leads to the development of liver damage, although several factors have been implicated including oxidative stress, mitochondrial abnormalities, and hormonal disturbances involving leptin and adiponectin. In particular, oxidative stress with subsequent lipid peroxidation and generation of reactive oxygen species seems to be prominent in NAFLD and has been identified as a therapeutic target for antioxidants. Injury by secondary insults leads to the generation of pro-inflammatory cytokines such as tumour necrosis factor α, which are targeted by hepatoprotective agents such as pentoxifylline. Hyperinsulinaemia and hyperglycaemia may also upregulate pro-fibrogenic cytokines and thus provide a rational for insulin sensitising agents such as metformin and the thiazolidinediones to prevent progressive liver damage.

NATURAL HISTORY

NAFLD exists as a histological spectrum of changes; simple steatosis refers to >5% hepatic steatosis in the absence of significant inflammation and hepatocellular damage whereas non-alcoholic steatohepatitis (NASH) demonstrates inflammation and hepatocellular damage and sometimes fibrosis. NAFLD may be progressive resulting in cirrhosis that may be complicated by hepatocellular carcinoma and liver failure. Overall, about 5% of patients with NAFLD develop cirrhosis over an average of a seven year period with 1.7% dying from complications of liver cirrhosis. The high prevalence and chronic nature NAFLD subsequently translates to a significant health burden for the general community. In addition, subjects with a diagnosis of NAFLD have a higher risk of all cause mortality than the general population. This may be partly related to an increased risk of liver related death, but may also be related to death from vascular disease as a result of underlying metabolic abnormalities and insulin resistance. Thus treatment of patients with NAFLD should aim to identify and treat associated metabolic factors such as obesity, glucose intolerance, dyslipidaemia, and hypertension. Secondly, treatment aimed at preventing progressive liver injury should be offered to those considered to be at risk. Diabetes mellitus and obesity are risk factors for progressive hepatic fibrosis and diabetes is also a risk factor for death in patients with NAFLD.

Histological features also assist in stratifying patient risk of progressive liver disease. Simple steatosis is comparatively benign with a 0%–4% risk of developing cirrhosis over a one to two decade period. In contrast, 5%–8% of patients with NASH may develop cirrhosis over approximately five years. Assessment of fibrosis stage is also valuable in prognosticating risk of developing liver related morbidity, with patients with advanced fibrosis (bridging fibrosis and cirrhosis) at most risk. Although these
features aid in stratifying patients at risk, a significant proportion of patients will have all of these adverse prognostic markers but will not develop liver related morbidity or mortality. Thus accurate prediction of those patients who will benefit most from treatment is difficult.

**DIAGNOSIS**

The diagnosis of NAFLD requires confirmation of hepatic steatosis by imaging or liver biopsy with clinical exclusion of excessive (>20 g/day) alcohol ingestion. Ultrasound, computed tomography, or magnetic resonance studies can confirm the presence of hepatic steatosis with a comparatively high degree of accuracy. Ultrasound is comparatively cheap and readily available but is less sensitive at detecting minimal (<30%) steatosis or among obese patients. Thus a negative ultrasound does not necessarily exclude NAFLD. Liver biopsy is the gold standard for diagnosis and is the only investigation able to distinguish between simple steatosis and NASH or stage the degree of fibrosis.

The decision to perform a liver biopsy must be individualised and may be useful when there is diagnostic uncertainty (for example, in the presence of raised iron parameters, auto-antibodies, or suspected coexisting drug toxicity) or to provide prognostication regarding outcome. Liver biopsy may also be performed in patients with risk factors of advanced fibrosis (diabetes, obesity, age >45, AST:ALT >1) where a diagnosis of cirrhosis has implications for screening for varices and hepatocellular carcinoma.

**TREATMENT**

Treatment strategies for NAFLD have revolved around (1) identification and treatment of associated metabolic conditions such as diabetes and hyperlipidaemia; (2) improving insulin resistance by weight loss, exercise, or pharmacotherapy; (3) using hepatoprotective agents such as antioxidants to protect the liver from secondary insults (fig 1). Many agents have shown promising results in preliminary pilot trials, however, there have been few treatment modalities examined in rigorous randomised double blind placebo controlled trials with adequate statistical power. Furthermore, interpretation of trials using biochemical markers of liver injury (for example, hepatic aminotransaminases) as treatment end points needs to be done cautiously, particularly in the absence of a control group. The natural history of patients with NAFLD and raised aminotransaminases is characterised by improvement of aminotransferases regardless of whether hepatic fibrosis improves or worsens.

**TREATMENT OF ASSOCIATED METABOLIC CONDITIONS**

The metabolic syndrome and its features of central obesity (waist circumference >94 cm for men, >80 cm for women), glucose intolerance (fasting glucose ≥6.10 mmol/l), hypertriglyceridaemia (>1.70 mmol/l), low HDL cholesterol (<1.03 mmol/l in women, <1.30 mmol/l in men), and hypertension (≥135/80 mm Hg) are associated with cardiovascular morbidity and mortality. These features are commonly present in subjects with NAFLD, with 67%–71% being obese, 12%–37% having impaired fasting glycaemia, 57%–68% having disturbed lipid profiles, and 36%–70% being hypertensive. Therefore, patients with newly diagnosed NAFLD should be screened for these conditions and appropriate treatment instituted in an effort to ameliorate the vascular risk as well as to improve NAFLD.

**WEIGHT LOSS AND EXERCISE**

Moderate amounts of weight loss as well as exercise are associated with improvement in insulin sensitivity and thus are logical treatment modalities for patients with NAFLD who are overweight or obese. Weight reduction may be achieved by caloric restriction from dieting, physical exercise, and/or pharmacotherapeutic agents as well as bariatric surgery in those patients with morbid obesity who are candidates for bariatric surgery.

Trials examining the effect of diet and exercise are non-randomised, of short duration with limited numbers of participants (table 2). Liver biochemistry and hepatic steatosis seem to improve, however, improvement in hepatic inflammation and fibrosis has not been seen, although this may be attributable to the lack of statistical power and inadequate treatment duration. It should be noted however, that rapid weight loss induced by very low energy diet (388 kcal/day) is associated with increased portal inflammation and serum bilirubin levels and thus should be avoided.

Energy restriction of about 25–30 kcal/kg/day seems reasonable with a target weight loss of about 10% of bodyweight over six months.

The optimal diet to treat NAFLD is not known. Patients with NAFLD seem more likely to have a diet high in saturated fats and cholesterol and low in fibre and antioxidants. Mono and poly-unsaturated fats may potentially improve insulin resistance and may be beneficial in improving hepatic steatosis. One small pilot trial of 23 NAFLD patients with hypertriglyceridaemia noted improvement of ALT levels with omega-3 fatty acid supplementation over six months, although effect on histology was not assessed. Most trials have used a diet similar to that recommended by the American Heart Association with energy restriction and energy intake composed of 40%–50% carbohydrates, 15%–20% protein, and 25%–40% predominately unsaturated fats. The effect of low (5%–10%) carbohydrate (Atkins diet) compared with standard (40%–60%) carbohydrate diet on NAFLD is unknown. Degree of weight loss is similar between diets after 12 months, although the low carbohydrate diet is associated with lower serum levels of triglyceride and higher HDL cholesterol levels. It should be noted that even under trial conditions and with frequent dietary assessments, compliance is poor with 30%–41% of participants dropping out emphasising the difficulty of maintaining weight loss through lifestyle change.

In an effort to assist weight loss, various pharmacotherapeutic agents have been evaluated. Orlistat is a lipase inhibitor that reduces fat absorption and promotes weight loss. A small pilot study showed improvement in aminotransaminases with a mean 10 kg weight loss after six months of orlistat. A non-significant reduction in steatosis was seen. Anorectic drugs such as fenfluramine and phentermine in addition to dietary and behavioural modifications were reported to improve aminotransaminase levels in 11 obese patients, but these drugs may induce cardiovascular and lung toxicity and they have been withdrawn.
from the market. More recently, sibutramine was associated with weight loss and improvement in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) over six months in 13 patients. Histology was not assessed, however, regression of hepatic steatosis as determined by ultrasound, occurred in 11 patients. The same series found similar improvements in 12 patients who were assigned to orlistat.

Among morbidly obese patients, several observational studies have shown consistent improvement in aminotransaminase levels and degree of hepatic steatosis after bariatric surgery. The effect on hepatic inflammation and fibrosis has been more variable. Malabsorptive bariatric procedures such as biliopancreatic diversion and jejunoeileal bypass are associated with an increase in hepatic fibrosis with cases of cirrhosis and liver related death reported after the latter procedure. In addition, rapid weight loss associated with gastric banding has been associated with an increase in lobular hepatitis, although this has not been a universal experience.

Several studies have examined weight loss in obese children with NAFLD. Diet and exercise leading to roughly 500 g/week weight loss in nine children, led to improvement in aminotransaminases and hepatic steatosis as determined by ultrasound. Similarly, weight loss from diet (1200–1400 calories/day) and exercise (at least six hours/week) was evaluated in 33 obese children aged between 4 and 16 years. Weight loss was associated with normalisation of liver tests and improvement or normalisation of hepatic steatosis on ultrasound. Improvement in aminotransaminases has also been reported in a series of six children with NAFLD, with fluctuating liver enzymes reported in those unable to lose weight.

In summary, the evidence of efficacy of diet and exercise in patients with NAFLD is surprisingly scant. However, as it is...
comparatively safe, inexpensive, and has other health benefits, it should remain the first line among patients with NAFLD and increased BMI. Patients with NAFLD and normal BMI still have some degree of insulin resistance; physical exercise in itself improves insulin resistance and thus NAFLD among subjects who are not obese or overweight based on BMI measurements. Some patients with normal BMI and NAFLD meet criteria for central obesity, and thus, waist circumference needs to be recorded in all patients with NAFLD regardless of BMI. Rapid weight loss attributable to very low calorie dieting or bariatric surgery risks exacerbation of liver injury and should be avoided. The risk/benefit of long term drugs for weight loss has not been clarified.

INSULIN SENSITISING DRUGS

It is well established that insulin resistance is a common association with patients with NAFLD and plays an important part in lipid accumulation within the liver and perhaps its progression to NASH. In keeping with this, insulin resistance is predictive of the necroinflammatory form of NAFLD and conditions associated with insulin resistance such as obesity and diabetes are associated with the presence of advanced fibrosis among subjects with NASH. This had provided the impetus to trial insulin sensitising drugs such as metformin and the thiazolidinediones in NAFLD.

Metformin is a biguanide antihyperglycaemic agent whose mechanism of action is not well understood. In animal models of fatty liver, metformin improved hepatic steatosis, which was accompanied by down-regulation of TNFα and lipid transcription factors. Several small pilot trials of four to six months’ duration using doses of 1–1.5 g/day, have showed improvement in ALT levels compared with baseline (table 3). Interestingly, a longer pilot trial using up to 2 g/day found no difference in ALT levels after 12 months’ treatment despite initial improvement at three months. Ten patients in this trial underwent biopsies at the end of treatment; improvement in steatosis was seen in one third of patients, inflammation in 20%, and fibrosis in 10%. A larger open label study from Italy randomised non-diabetic subjects to 2 g/day metformin (n = 55), diet (n = 27), or 800 IU/day vitamin E (n = 28). Significantly more subjects taking metformin had normalisation of ALT levels compared with those taking vitamin E or diet treatment. Follow up liver biopsy was performed in 17 of the 55 subjects assigned to metformin therapy; significant improvements were seen in steatosis, inflammation, and fibrosis compared with baseline. Although encouraging, these results need to be reproduced in larger and well controlled clinical trials before assuming metformin is an effective and safe treatment for patients with NAFLD.

Lactic acidosis is a feared complication of metformin therapy, although it is rare and primarily seen among patients with renal or cardiac failure. However, the risk among patients with advanced liver fibrosis has not been well studied. In the few studies to date, 0%–7% of patients taking metformin therapy had increased lactate levels but not acidosis. Very few patients taking metformin had cirrhosis and thus it remains unclear whether it is safe to prescribe metformin in these patients.

The thiazolidinediones bind to the peroxisome proliferator activated receptor γ (PPAR) resulting in improved insulin sensitivity and redistribution of adipose tissue. In animal models, PPARγ agonists also have a protective effect against liver fibrosis by inhibiting activation of hepatic stellate cells. Troglitazone showed promising results in a pilot trial before being removed from the market because of idiosyncratic liver toxicity. The second generation “glitazones” rosiglitazone and pioglitazone are structurally different to troglitazone and seem to be safer.

Two well designed pilot trials using pioglitazone (30 mg daily) and rosiglitazone (4 mg twice daily) showed improvement in ALT, hepatic steatosis, and features of hepatic inflammation compared with baseline. Pioglitazone but not rosiglitazone was associated with improvement in the overall fibrosis stage. A randomised trial of 20 non-diabetic patients with NASH comparing pioglitazone (30 mg/day) plus vitamin E (400 IU/day) with vitamin E (400 IU/day) alone, found both groups improved hepatic steatosis grade compared with baseline, although the degree of improvement with pioglitazone was greater; features of hepatic inflammation also improved in the pioglitazone group compared with baseline. Comparing treatments at the end of the study however, found no difference in ALT, steatosis grade, or fibrosis stage between groups, although hepatic inflammation were significantly less in the pioglitazone group. Interpretation of these studies without a placebo group is difficult, as ALT levels, hepatic steatosis, and inflammation tend to improve over time as fibrosis progresses in NAFLD. Weight gain with fat redistribution from the central/trunkal area to the lower body was the most common side effect occurring in 67%–72% of subjects taking pioglitazone or rosiglitazone. Of concern, 1 of 30 subjects in the rosiglitazone trial and 1 of 10 patients taking pioglitazone were withdrawn because of hepatotoxicity. Although definitive cause-effect was not proved, potential hepatotoxicity in the setting of liver disease remains a concern.

ANTIOXIDANTS

Subjects with NAFLD exhibit increased levels of oxidative stress and lipid peroxidation that may play a part in disease progression and fibrosis. The mechanism of action is not well understood. In animal models of fatty liver, metformin improved hepatic steatosis, which was accompanied by down-regulation of TNFα and lipid transcription factors. Several small pilot trials of four to six months’ duration using doses of 1–1.5 g/day, have showed improvement in ALT levels compared with baseline (table 3). Interestingly, a longer pilot trial using up to 2 g/day found no difference in ALT levels after 12 months’ treatment despite initial improvement at three months. Ten patients in this trial underwent biopsies at the end of treatment; improvement in steatosis was seen in one third of patients, inflammation in 20%, and fibrosis in 10%. A larger open label study from Italy randomised non-diabetic subjects to 2 g/day metformin (n = 55), diet (n = 27), or 800 IU/day vitamin E (n = 28). Significantly more subjects taking metformin had normalisation of ALT levels compared with those taking vitamin E or diet treatment. Follow up liver biopsy was performed in 17 of the 55 subjects assigned to metformin therapy; significant improvements were seen in steatosis, inflammation, and fibrosis compared with baseline. Although encouraging, these results need to be reproduced in larger and well controlled clinical trials before assuming metformin is an effective and safe treatment for patients with NAFLD.

**Table 3** Insulin sensitising agents in the treatment non-alcoholic fatty liver disease

<table>
<thead>
<tr>
<th>Author</th>
<th>Intervention</th>
<th>Number</th>
<th>Study type</th>
<th>Duration (months)</th>
<th>ALT</th>
<th>Steatosis</th>
<th>Inflammation</th>
<th>Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magalotti</td>
<td>Metformin</td>
<td>11</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>6</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Schwimmer</td>
<td>Metformin</td>
<td>10</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Nair</td>
<td>Metformin</td>
<td>15</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>4</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Marchesi</td>
<td>Metformin</td>
<td>14</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Buganiesi</td>
<td>Metformin</td>
<td>110</td>
<td>Open label, randomised</td>
<td>Vitamin E or diet</td>
<td>11</td>
<td>Improved</td>
<td>Improved</td>
<td>Improved</td>
</tr>
<tr>
<td>Promrat</td>
<td>Pioglitazone</td>
<td>18</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Boda</td>
<td>Pioglitazone</td>
<td>11</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>11</td>
<td>Improved</td>
<td>Improved</td>
<td>Improved</td>
</tr>
<tr>
<td>Shadid</td>
<td>Pioglitazone</td>
<td>5</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>4</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Neuschwander</td>
<td>Rosiglitazone</td>
<td>30</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>11</td>
<td>Improved</td>
<td>Improved</td>
<td>Improved</td>
</tr>
<tr>
<td>Tehan</td>
<td>Pioglitazone + vitamin E</td>
<td>20</td>
<td>Open label, randomised</td>
<td></td>
<td>6</td>
<td>No difference</td>
<td>No difference</td>
<td>Improved</td>
</tr>
</tbody>
</table>

* Determined by magnetic resonance spectroscopy; † Improvement seen in zone 3 fibrosis but not overall fibrosis score.
Vitamin E is a potent antioxidant and has been evaluated among paediatric and adult patients with NAFLD (table 4). Two small pilot trials have shown reduction of ALT levels among adult and paediatric patients with NASH. Subsequently, two small randomised controlled trials have failed to show any benefit of vitamin E on ALT levels; one study randomised 16 adult subjects to vitamin E (800 IU/day) or no treatment over three months; the other trial consisted of 28 obese children taking vitamin E (400 mg/daily for two months, 100 mg/daily for three months) or placebo. In the only randomised study assessing histology, Harrison and colleagues randomised 45 patients to vitamins E (1000 mg/day) and C (1000 mg/day) or placebo for six months. Vitamin treatment significantly improved hepatic inflammation and fibrosis compared with baseline. However, the comparison of changes between placebo and vitamin E/C groups occurring with treatment at the end of the study showed no differences in ALT, hepatic inflammation or fibrosis. Recent evidence has also suggested that vitamin E supplementation may not be innocuous but may be associated with an increased risk of death and heart failure. Therefore in the absence of convincing evidence of benefit and the possible spectre of harm, vitamin E cannot be recommended for treatment of NAFLD outside of clinical trials.

Probufol is a lipid lowering antioxidant, which after showing promise in a pilot trial, improved ALT levels compared with placebo in a six month randomised trial. However, probucol is not universally available and has been withdrawn from Australia and the USA after concern regarding its pro-arrhythmic potential.

OTHER HEPATO-PROTECTIVE AGENTS

A variety of hepatoprotective agents used in other liver disease have been evaluated in patients with NAFLD (table 5). Pentoxifylline inhibits TNFα and has been shown to improve short term survival in severe alcoholic hepatitis. Early pilot trials have shown improvement in aminotransaminases in NAFLD patients with 1200–1600 mg/daily of pentoxifylline. Similarly, betaine, a methyl donor that protects NAFLD patients with raised liver enzymes may not be at increased risk of serious hepatotoxicity with standard doses of these drugs. Subsequently two small pilot trials have shown improvement of liver enzymes with atorvastatin. As hypertriglyceridaemia and low HDL cholesterol levels are a manifestation of insulin resistance and common among subjects with NAFLD, several investigators have used lipid lowering drugs to treat NAFLD (table 5). The use of statin drugs is currently contraindicated in the presence of active liver disease or persistent unexplained increases of aminotransaminases. Recent evidence, however, shows that patients with raised liver enzymes may not be at increased risk of serious hepatotoxicity with standard doses of these drugs. Consequently, probiotics have been shown to ameliorate liver injury in these models. Administration of the probiotic VSL no 3 to 22 NAFLD patients over three months improved ALT levels as well as markers of lipid peroxidation. Effects on histology are unknown.

LIPID LOWERING DRUGS

As hypertriglyceridaemia and low HDL cholesterol levels are a manifestation of insulin resistance and common among subjects with NAFLD, several investigators have used lipid lowering drugs to treat NAFLD (table 5). The use of statin drugs is currently contraindicated in the presence of active liver disease or persistent unexplained increases of aminotransaminases. Recent evidence, however, shows that patients with raised liver enzymes may not be at increased risk of serious hepatotoxicity with standard doses of these drugs. Subsequently two small pilot trials have shown improvement of liver enzymes with atorvastatin. In addition, pravastatin 20 mg given for six months normalised liver enzymes and improved hepatic inflammation among five patients with NASH. Two small trials have also examined the fenofibrate; one 12 month trial of clofibrate showed no change in ALT, hepatic inflammation or fibrosis.

Table 4: Hepatoprotective agents in the treatment of non-alcoholic fatty liver disease

<table>
<thead>
<tr>
<th>Author</th>
<th>Intervention</th>
<th>Number</th>
<th>Study type</th>
<th>Comparison</th>
<th>Duration (months)</th>
<th>ALT</th>
<th>Histology</th>
<th>Steatosis</th>
<th>Inflammation</th>
<th>Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauzon</td>
<td>UDCA</td>
<td>24</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>Improved</td>
<td>Improved</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Kyici</td>
<td>UDCA</td>
<td>17</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>6</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vajro</td>
<td>UDCA</td>
<td>31</td>
<td>Open label, randomised diet</td>
<td>Diet</td>
<td>6</td>
<td>No difference</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No change</td>
</tr>
<tr>
<td>Lindor</td>
<td>UDCA</td>
<td>166</td>
<td>Blinded RCT</td>
<td>Placebo</td>
<td>24</td>
<td>No difference</td>
<td>No difference</td>
<td>No difference</td>
<td>No difference</td>
<td></td>
</tr>
<tr>
<td>Abdelmalek</td>
<td>Betaine</td>
<td>10</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>Improved</td>
<td>Improved</td>
<td>No difference</td>
<td>No difference</td>
<td>No change</td>
</tr>
<tr>
<td>Meraf</td>
<td>Probucol</td>
<td>17</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>6</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Merat</td>
<td>Probucol</td>
<td>30</td>
<td>Blinded RCT</td>
<td>Placebo</td>
<td>6</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Adams</td>
<td>Pentoxifylline</td>
<td>20</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Satapathy</td>
<td>Pentoxifylline</td>
<td>18</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>6</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Loguerico</td>
<td>VSL no 3</td>
<td>22</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>3</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Yokahama</td>
<td>Losartan</td>
<td>7</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>11</td>
<td>Improved</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Hasegawa</td>
<td>Vitamin E</td>
<td>22</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>12</td>
<td>Improved</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Kugelmas</td>
<td>Vitamin E + diet</td>
<td>16</td>
<td>Open label, randomised exercise</td>
<td>Diet and exercise</td>
<td>3</td>
<td>No difference</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No change</td>
</tr>
<tr>
<td>Vajro</td>
<td>Vitamin E</td>
<td>28</td>
<td>Blinded RCT</td>
<td>Placebo</td>
<td>5</td>
<td>No difference</td>
<td>No difference</td>
<td>NA</td>
<td>No change</td>
<td></td>
</tr>
<tr>
<td>Harrison</td>
<td>Vitamin E + C</td>
<td>45</td>
<td>Blinded RCT</td>
<td>Placebo</td>
<td>6</td>
<td>No difference</td>
<td>No difference</td>
<td>No change</td>
<td>No change</td>
<td></td>
</tr>
<tr>
<td>Lavine</td>
<td>Vitamin E</td>
<td>11</td>
<td>Pilot trial</td>
<td>Baseline</td>
<td>5</td>
<td>Improved</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*“No change” if no statistically significant change reported. Assessed by ultrasound.*
2 g/day showed no improvement in liver enzymes or histology, whereas gemfibrozil 600 mg/day improved ALT levels compared with no treatment over four weeks of treatment.\textsuperscript{89}

**FUTURE DIRECTIONS**

Increased understanding of the pathogenesis of NAFLD and particularly the factors responsible for progressive liver injury, will permit better targeting of therapeutic agents. Adiponectin is a hormone secreted by adipose tissue that has insulin sensitising as well as apparent hepatoprotective effects and thus may play a part in hepatic fat accumulation as well as liver injury in patients with NAFLD. Supplementation of adiponectin led to improvement in hepatic steatosis and ALT levels to animal models of NAFLD. Human studies have not been performed.

Agonists of PPAR\textgreek{y} (thioglitazones) and PPAR\textgreek{a} (fibrates) act to improve insulin sensitivity and up-regulate hepatic FFA oxidation thus decreasing hepatic steatosis. Both types of agonists have shown promising results in pilot trials in NAFLD. Combination dual PPAR \textgreek{g} and \textgreek{a} agonists (muraglitazar, tesaglitazar) would therefore seem to be attractive candidates for treatment of NAFLD. Phase 2 clinical trials are currently underway examining the influence of these agents on cardiovascular risk factors.\textsuperscript{91}

**CONCLUSIONS**

NAFLD is now acknowledged to be the commonest liver condition in the western world, largely because of the considerable increase in metabolic diseases such as obesity and diabetes. It is clear that NAFLD leads to liver related morbidity and mortality in a subset of people, particularly those who are obese, diabetic, and who have NASH. However, a better understanding of the natural history of NAFLD will permit better identification of at risk patients who should be targeted for long term and potentially expensive treatment.

Treatment of NAFLD should begin with screening and managing metabolic risk factors that may modify the risk of liver disease as well as non-liver related disease such as ischaemic heart disease. First line treatment should consist of lifestyle change with weight loss and exercise to improve insulin sensitivity. However, because of long term compliance difficulties, pharmaceutical agents aimed at reducing insulin resistance or protecting the liver from additional insults are needed.

Many pilot trials have shown promising initial results in improving liver enzymes or features of liver histology. However, the efficacy of these agents still remains in question, and none of them can yet be recommended outside of clinical trials. Furthermore, the cost effectiveness of pharmacological therapy of NAFLD has to be defined. Some randomised, double blind, placebo controlled trials evaluating pioglitazone, metformin, vitamin E, betaine, and silymarin are currently in progress, in both adults and children. These trials will hopefully provide new therapeutic options for the clinician in the near future.

**MULTIPLE CHOICE QUESTIONS (TRUE (T)/FALSE (F); ANSWERS AT END OF REFERENCES)**

1. Treatment of nonalcoholic fatty liver disease (NAFLD) should be aimed at preventing its progression to the following complications;

(A) cirrhosis
(B) hepatocellular carcinoma
(C) liver failure
(D) liver abscess

2. The following are adverse prognostic indicators among patients with NAFLD;

(A) obesity
(B) cirrhosis
(C) raised aminotransaminases
(D) diabetes

3. The following treatments should be routinely recommended for patients with NAFLD;

(A) weight loss if obese
(B) exercise
(C) reduction of excessive alcohol ingestion
(D) thiazolidinediones

---

**Learning points**

**Metabolic risk factors for NAFLD**
- Central obesity (waist circumference \(\geq 94\) cm for men, \(\geq 80\) cm for women)
- Impaired fasting glycaemia (\(\geq 6.1\) mmol/l)
- Hypertriglyceridaemia (\(>1.70\) mmol/l)
- Low HDL-cholesterol (\(<1.30\) mmol/l in men, \(<1.03\) mmol/l in women)
- Hypertension (\(\geq 135/80\) mm Hg)

**Treatment recommendations for NAFLD**
- Exclude secondary causes of hepatic steatosis
- Screen for metabolic risk factors
- Avoid hepatotoxins such as alcohol excess
- Regular exercise
- Weight loss if centrally obese
- Consider bariatric surgery if morbidly obese
4. With regard to weight loss in obese patients with NAFLD:
(A) it should be gradual and medically supervised
(B) total starvation or very low energy diets are safe and effective
(C) it is difficult to achieve and maintain by most obese patients
(D) the available antiobesity drugs have shown to prevent progression to cirrhosis

5. The following drugs have been conclusively shown to improve liver histology among patients with NAFLD:
(A) metformin
(B) pioglitazone
(C) vitamin E
(D) ursodeoxycholic acid

Authors’ affiliations
L A Adams, School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Perth, Australia
P Angulo, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, USA
Funding: LA is supported by a Postgraduate Medical Research Scholarship (no. 053710) from the National Health and Medical Research Council as well as by the Astelion and Amy Saw Postgraduate Medical Scholarship from The University of Western Australia.
Conflicts of interest: none declared.

REFERENCES